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Hematopoietic cell transplantation (HCT) is widely used as a treatment for acquired and congenital disorders. In recent years, 
a significant increase in transplant activity around the world has been observed, especially in Eastern European countries. This article 
aimed to assess progress and trends in pediatric HCT in Central-Eastern European countries between 2013 and 2018. Transplant activity 
survey in 2013 and 2018 in nine Central-Eastern European countries (Czech Republic, Croatia, Hungary, Lithuania, Poland, Romania, 
Slovakia, Slovenia, and Ukraine) was performed. The highest transplant rates in total were found in the Czech Republic and Hungary. 
When calculated per 10 million of the pediatric population, a 25.9% increase in the number of allo-HCT was observed with the highest 
in Croatia, Romania, Lithuania, and Poland; and a 12.2% increase in the number of auto-HCT was observed with the highest in Slovenia, 
Slovakia, Romania, Poland, Ukraine, and Croatia. We have shown, over the years 2013 and 2018, in some countries of Central-Eastern 
Europe that there was a significant increase in transplant activity, especially in those with the lower rates. This increase was observed 
mainly in centers already existing in 2013, especially in the allo-HCT setting. The rise of activity was significantly less influenced by the 
creation of new transplant centers or the increase in the number of pediatric transplant beds. In conclusion, our analysis indicates that 
in the Czech Republic, Hungary, Lithuania, and Slovenia, the actual infrastructure and the number of HCTs cover the needs, whereas in 
other countries, especially in Romania and Ukraine, the number of HCT needs to be increased.
©  2020 Polish Society of Hematology and Transfusion Medicine, Insitute of Hematology and Transfusion Medicine. Published by Sciendo. 
All rights reserved.
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Introduction
Hematopoietic cell transplantation (HCT) is a method 
of treatment for many congenital and acquired 
hematological diseases and organ malignancies [1]. 
According to the European Society for Blood and 
Marrow Transplantation (EBMT) activity survey in 
2013, a record number of 39,209 HCT in 34,809 
patients performed in Europe and associated 
countries was reported, whereas in 2018 this number 
raised to 47,468 HCT in 42,901 patients [2, 3]. The 
EBMT activity survey has been conducted each year 
since 1990 [4], therefore, we can follow not only the 
increasing number of HCT every year but also the 
changing trends regarding the source of the stem 
cells, type of transplant, or indications for transplant 
procedures. Since the 2012 EBMT survey, we could 
observe HCT activity in pediatric transplants performed 
either in dedicated pediatric HCT centers or in centers 
performing transplants in both adult (>18 years of age 
at transplant) and pediatric patients [5].
In the 2014 EBMT activity survey, a significant 
increase in HCTs in Eastern European countries was 
reported for the first time [6], with the highest increase 
for allogeneic HCT (allo-HCT) in Romania, Russia, 
Turkey, Croatia, and Serbia and autologous HCT 
(auto-HCT) in Romania, Serbia, and Russia as well 
as in Turkey and Iran [6].
The last report on survey activity (1985–2004) in 
pediatric HCT setting in Eastern European countries 
was published in 2008 [7], and to our knowledge, no 
other publication was done in this field. Due to observed 
changes in pediatric hematopoietic transplantation in 
Central-Eastern Europe, we have decided to analyze 
the progress over the past 5 years. This report is based 
on the data collected from an activity survey in 2013 
and 2018 in nine Central-Eastern European countries 
(Czech Republic, Croatia, Hungary, Lithuania, Poland, 
Romania, Slovakia, Slovenia, and Ukraine).
The objective of this study was to assess progress 
and trends in pediatric HCT in Central-East European 
countries in the last 5 years.
Patients and methods
Design of the study
Centers coordinating pediatric HCT in Central-Eastern 
European countries were invited to participate in the 
survey on the current situation and transplant activity, 
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in the pediatric setting, as listed in table I. This report presents the 
results of the survey activity in 2013 and 2018.
Data collection
In November 2019, a survey on transplant activity in a pediatric 
setting was distributed by e-mail. The main national center collected 
data from other centers in the country. Collected data were sent to 
the coordinating center in the Department of Pediatric Hematology 
and Oncology, Collegium Medicum, Nicolaus Copernicus University 
Torun, Antoni Jurasz University Hospital in Bydgoszcz, Bydgoszcz, 
Poland.
There was no need for Bioethical Committee approval for this study, 
as no study on patients was performed. All participants of the survey 
are co-authors of this manuscript and have given their agreement for 
publication.
Pediatric population and transplant rates
The pediatric population was defined as all individuals aged from 0 
to 18 years in each analyzed year. Transplant rates were calculated 
as a total HCT per 10 million (M) of the pediatric population in each 
country without correction for patients traveling to a foreign country 
to receive HCT. For each country, total population numbers and 
pediatric population numbers were obtained from Eurostat’s for 
2013 and 2018 (https://ec.europa.eu/eurostat/data/database). We 
considered an increase or decrease of ± 5% as a non-relevant 
change. Transplant rates were categorized as low (<100), moderate 




We sent a survey to Central-Eastern European countries/national 
coordinators. Complete data were returned from eight countries 
(Czech Republic, Croatia, Hungary, Lithuania, Poland, Romania, 
Slovakia, and Slovenia) and were analyzed (Tab. I, Fig. 1). The data 
received from Ukraine were not sufficient to perform a full analysis.
The Czech Republic
Czech Republic’s pediatric population increased by 6.0% between 
2013 and 2018 (from 1.839 M to 1.949 M). In 2013 and 2018, there 
were two pediatric HCT centers: in Brno specialized in auto-HCT 
and Prague performing both allo- and auto-HCT. The total number 
of pediatric transplant beds did not change in the analyzed period, 
however, calculated per 10 M pediatric population, the number 
of pediatric HCT beds was 65.2 in 2013 and 61.6 in 2018 (5.6% 
decrease due to population increase). An increasing trend was 
observed in the number of allo- and auto-HCT. A total of 30 allo-HCT 
were performed in 2013, while 37 in 2018 (23.3% increase). When 
calculated per 10 M of the pediatric population, a 16.4% increase was 
Fig. 1.  Percentage of increase/decrease in HCT activity between 2013 and 2018 in reported countries (no possibility to calculate 
change for Ukraine)
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Table I. Number of HCT in children in Central-East Europe countries in 2013 and 2018  
COUNTRY CZECH REPUBLIC CROATIA HUNGARY LITHUANIA POLAND
YEAR 2013 2018 Change 
(%)
2013 2018 Change 
(%)
2013 2018 Change 
(%)
2013 2018 Change 
(%)
2013 2018 Change 
(%)
Popultion (Eurostat)[mln] 10.516 10.610 0.9 4.262 4.105 -3.7 9.908 9.778 -1.3 2.971 2.808 -5.5 38.062 37.977 -0.2
Pediatric population 
(Eurostat)[mln]
1.839 1.949 6.0 0.786 0.717 -8.8 1.758 1.715 -2.4 0.544 0.503 -7.5 7.005 6.874 -1.9
Number of pediatric HCT 
centers
2 2 0.0 2 2 0.0 2 2 0.0 1 1 0.0 5 6 20.0
Number of pediatric 
transplant beds
12 12 0.0 3 3 0.0 16 16 0.0 4 6 50.0 35 45 28.6
Number of allo-HCT 30 37 23.3 3 12 300.0 33 33 0.0 9 11 22.2 114 146 28.1
Number of auto-HCT 33 36 9.1 5 5 0.0 24 12 -50.0 8 5 -37.5 34 39 14.7
Total number of allo-HCT 
and auto-HCT
63 73 15.9 8 17 112.5 57 45 -21.1 17 16 -5.9 148 185 25.0
Number of HCT in ALL 9 12 5 4 13 4 5 2 33 60
Number of HCT in AML 4 8 1 1 4 3 1 2 24 20
Number of HCT in MDS 6 5 0 1 5 14 1 1 9 16
Number of HCT in CML 1 0 0 0 0 0 0 0 2 2
Number of HCT in NHL 0 2 0 0 4 0 1 1 8 6
Number of HCT in HL 1 1 0 0 2 0 3 2 4 7
Number of HCT in SAA/
BMF
1 7 1 2 2 2 1 2 15 17
Number of HCT in NBL 12 9 4 5 6 3 2 1 20 22
Number of HCT in Ewing 
sarcoma
5 4 1 0 3 4 3 2 5 6
Number of HCT in primary 
immunodeficiency
7 3 1 3 3 2 0 3 21 16
Number of HCT in meta-
bolic disorders
2 0 0 0 1 0 0 0 0 5
Number of pediatric HCT 
centers/10 mln of pediat-
ric population
10.9 10.3 -5.6 25.4 27.9 9.7 11.4 11.7 2.5 18.4 19.9 8.1 7.1 8.7 22.3
Number of pediatric 
transplant beds/10 mln of 
pediatric population
65.2 61.6 -5.6 38.2 41.9 9.7 91.0 93.3 2.5 73.6 119.3 62.1 50.0 65.5 31.0
Number of allo-HCT/
10 mln of pediatric pop-
ulation
163.1 189.9 16.4 38.2 167.4 338.7 187.8 192.4 2.5 166.5 218.7 32.1 162.7 212.4 30.5
Number of auto-HCT/
10 mln of pediatric pop-
ulation
179.4 184.7 3.0 63.6 69.8 9.7 136.6 70.0 -48.8 147.1 99.4 -32.4 48.5 56.7 16.9
Total number of allo-HCT 
and auto-HCT/10 mln of 
pediatric population
342.5 374.6 9.4 101.8 237.2 133.1 324.3 262.4 -19.1 312.6 318.1 1.7 211.3 269.1 27.4
AML – acute myelogenous leukemia; ALL – acute lymphoblastic leukemia; allo-HCT – allogeneic hematopoietic cell transplantation; auto-HCT – autologous hematopoietic cell transplan-
tation; BMF – bone marrow failure; CML – chronic myelogenous leukemia; ES – Ewing’s sarcoma; HCT – hematopoietic cell transplantation; HL – Hodgkin’s lymphoma; MDS – myelodys-
plastic syndrome; n.d. – no data; NBL – neuroblastoma; NHL – non-Hodgkin’s lymphoma; PID – primary immunodeficiency; SAA – severe aplastic anemia; * – data not including Ukraine
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continued Table I. 
COUNTRY ROMANIA SLOVAKIA SLOVENIA UKRAINE TOTAL
YEAR 2013 2018 Change 
(%)
2013 2018 Change 
(%)
2013 2018 Change 
(%)
2013 2018 Change 
(%)
2013 2018 Change 
(%)
Popultion (Eurostat)[mln] 20.020 19.531 -2.4 5.410 5.443 0.60 2.058 2.067 0.4 45.373 42.217 -7.0 138.6 134.5 -2.9
Pediatric population 
(Eurostat)[mln]
3.786 3.681 -2.8 1.075 1.062 -1.2 0.356 0.366 3.0 7.990 7.609 -4.8 25.1 24.5 -2.6
Number of pediatric HCT 
centers
2 2 0.0 1 1 0.0 1 1 0.0 3 3 0.0 19 20 5.3
Number of pediatric 
transplant beds
9 11 22.2 6 6 0.0 2 2 0.0 9 11 22.2 96 112 16.7
Number of allo-HCT 9 18 100.0 12 14 16.7 8 5 -37.5 21 17 -19.0 239 293 22.6
Number of auto-HCT 13 22 69.2 5 11 120.0 2 5 150.0 39 43 10.2 163 178 9.2
Total number of allo-HCT 
and auto-HCT
22 40 81.8 17 25 47.1 10 10 0.0 60 60 0 402 471 17.2
Number of HCT in ALL 2 6 4 6 2 4 n.d. 4 73* 98* 34.2*
Number of HCT in AML 4 3 3 2 2 0 n.d. 3 43* 39* -9.3*
Number of HCT in MDS 0 2 0 2 0 0 n.d. 1 21* 41* 95.2*
Number of HCT in CML 1 0 0 0 0 0 n.d. 0 4* 2* -50.0*
Number of HCT in NHL 2 0 0 0 0 0 n.d. 2 15* 9* -40.0*
Number of HCT in HL 5 10 0 0 0 0 n.d. 2 15* 20* 33.3*
Number of HCT in SAA/
BMF
2 4 1 1 2 0 n.d. 3 25* 35* 40.0*
Number of HCT in NBL 5 12 3 8 1 2 10 28 63 90 42.9
Number of HCT in Ewing 
sarcoma
1 2 1 0 1 0 5 10 25 28 12
Number of HCT in primary 
immunodeficiency
0 1 3 1 1 1 n.d. 2 36* 30* -16.7*
Number of HCT in meta-
bolic disorders
0 0 1 0 1 0 n.d. 0 5* 5* 0.0*
Number of pediatric HCT 
centers/10 mln of pediat-
ric population
5.3 5.4 2.9 9.3 9.4 1.2 28.1 27.3 -2.9 3.7 3.9 5.0 7.6 8.2 8.1
Number of pediatric 
transplant beds/10 mln of 
pediatric population
23.8 29.9 25.7 55.8 56.5 1.2 56.2 54.6 -2.9 11.3 14.4 28.3 38.2 45.8 19.8
Number of allo-HCT/10 
mln of pediatric popu-
lation
23.8 48.9 105.7 111.6 131.7 18.0 224.7 136.4 -39.3 26.3 22.3 -15.0 95.1 119.7 25.9
Number of auto-HCT/10 
mln of pediatric popu-
lation
34.3 59.8 74.1 46.5 103.5 122.6 56.2 136.4 142.8 48.8 56.5 15.8 64.8 72.7 12.2
Total number of allo-HCT 
and auto-HCT/10 mln of 
pediatric population
58.1 108.7 87.0 158.1 235.2 48.8 280.9 272.8 -2.9 75.1 78.9 5.0 159.9 192.4 20.3
AML – acute myelogenous leukemia; ALL – acute lymphoblastic leukemia; allo-HCT – allogeneic hematopoietic cell transplantation; auto-HCT – autologous hematopoietic cell transplan-
tation; BMF – bone marrow failure; CML – chronic myelogenous leukemia; ES – Ewing’s sarcoma; HCT – hematopoietic cell transplantation; HL – Hodgkin’s lymphoma; MDS – myelodys-
plastic syndrome; n.d. – no data; NBL – neuroblastoma; NHL – non-Hodgkin’s lymphoma; PID – primary immunodeficiency; SAA – severe aplastic anemia; * – data not including Ukraine
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observed (from 163.1 allo-HCT per 10 M pediatric population in 2013 
to 189.9 allo-HCT per 10 M pediatric population in 2018). A total of 33 
auto-HCT were performed in 2013, while 36 in 2018 (9.1% increase). 
When calculated for 10 M of the pediatric population, an insignificant 
3.0% increase was observed (from 179 auto-HCT per 10 M pediatric 
population to 185 auto-HCT per 10 M pediatric population). The 
total number of auto- and allo-HCT calculated per 10 M pediatric 
population increased from 342.5 in 2013 to 374.6 in 2018 (9.4% 
increase).
The main indication for allo-HCT was acute lymphoblastic leukemia 
(ALL) and acute myeloid leukemia (AML), while neuroblastoma (NBL) 
and Ewing’s sarcoma (ES) for auto-HCT, both in 2013 and 2018. In 
2013, one patient was transplanted due to chronic myelogenous 
leukemia (CML) and none in 2018. A significant increase (600.0%) 
of allo-HCT was observed in severe aplastic anemia (SAA) and bone 
marrow failure (BMF) (one in 2013 and seven in 2018). Besides natural 
fluctuations in annual disease incidence, this may reflect a change in 
the indications toward frontline HCT using rapidly available matched 
unrelated donors instead of primary immunosuppressive therapy.
As early as 2013, the Czech Republic was among the countries with 
a very high transplant rate per 10 M of the pediatric population (the 
highest number of HCTs per 10 M of pediatric population, among 
analyzed countries). We assume that the number of centers, pediatric 
beds, and transplants covers current country needs.
Croatia
Croatian pediatric population decreased from 0.786 M children in 
2013 to 0.717 M in 2018 (8.8% decrease). There are two HCT centers 
performing transplantation in children, both in Zagreb: one joint 
adult-pediatric center performing allo- and auto-HCT, and the other 
performing only auto-HCT for children. The total number of pediatric 
transplant beds is three. Both, the number of pediatric transplant 
centers and beds did not change between 2013 and 2018. Calculated 
per 10 M pediatric population, the number of pediatric HCT beds was 
38.2 in 2013 and 41.9 in 2018, respectively (the observed increase 
is caused by the decrease in the pediatric population). An increasing 
trend was observed in the number of allo-HCT from 3 in 2013 to 12 
transplants in 2018 (i.e., an increase of 300.0%). Calculated per 10 M 
of the pediatric population, an increase of 338.7% was observed 
(from 38 to 167 transplants per 10 M of the pediatric population). 
Although the number of autologous transplants in 2013 and 2018 
is the same (five transplants/year), there is a 9.7% increase in the 
number of auto-HCT per 10 M of the pediatric population (from 63.6 
to 69.8 transplants per 10 M pediatric population) due to decrease 
of the pediatric population. The total number of auto- and allo-HCT 
calculated per 10 M pediatric population has increased from 101.8 in 
2013 to 237.2 in 2018 (133.1% increase).
The main indication for allo-HCT was ALL and high-risk NBL for auto-
HCT, both in 2013 and 2018. More patients were transplanted in 2018 
due to SAA, BMF, and primary immunodeficiency (PID) compared to 
2013. No patient was transplanted due to CML.
Despite an observed increase, the number of transplants per 10 M 
of the pediatric population in both 2013 and 2018 has shifted Croatia 
from the group of countries with a moderate number of transplants 
(101–200 transplants per 10 M of the pediatric population/year) in 
2013 to a high number of transplants (201–300 transplantations per 
10 M pediatric population/year) in 2018. We could expect a further 
increase in the number of transplants in subsequent years.
Hungary
Hungarian pediatric population insignificantly decreased by 2.4% 
between 2013 and 2018 (from 1.758 M to 1.715 M). In 2013 and 
2018, there were two pediatric HCT centers (Budapest and Miskolc) 
performing allo- and auto-HCT in children. The total number of 
pediatric transplant beds did not change between 2013 and 2018 
(16 beds). Calculated per 10 M pediatric population, the number of 
pediatric HCT beds was 91.0 in 2013 and 93.3 in 2018 (insignificant 
2.5% increase due to population decrease). The number of allo-HCT 
did not change in 2013 and 2018 (33 allo-HCT/year). The calculated 
ratio for 10 M of the pediatric population did not change (187.8 in 
2013 and 192.4 in 2018 representing 2.4% insignificant increase 
due to population decrease). Significantly, a 50.0% decrease was 
observed in the case of auto-HCT (from 24 in 2013 to 12 in 2018). 
When calculated for 10 M of the pediatric population, a 48.8% 
decrease was observed (from 136.6 auto-HCT per 10 M pediatric 
population in 2013 to 70.0 auto-HCT per 10 M pediatric population in 
2018). The total number of auto- and allo-HCT calculated per 10 M 
pediatric population decreased from 324.3 in 2013 to 262.4 in 2018 
(19.1% decrease).
The main indication for allo-HCT was ALL in 2013 and myelodysplastic 
syndrome (MDS) in 2018, while NBL and ES for auto-HCT in 2013 and 
2018. There was a significant decrease in the number of HCT in ALL 
and NBL patients (decrease from 13 in 2013 to 4 in 2018 in ALL and 
decrease from 6 in 2013 to 3 in 2018 in NBL). No HCT due to CML was 
performed in 2013 and 2018, while the number of transplantations 
due to SAA/BMF did not change (two transplantations/year).
Our analysis indicates that in 2013, Hungary was among the countries 
with a very high transplant rate per 10 M of the pediatric population. 
Most probably the number of centers, pediatric beds, and the number 
of transplants cover current country needs.
The observed decrease in 2018 in the number of transplants 
is probably due to periodic fluctuations in the number of cases, 
especially ALL being the main pediatric indication for allo-HCT.
Lithuania
Lithuanian pediatric population decreased by 7.5% between 2013 
and 2018 (from 0.544 M to 0.503 M). In 2013 and 2018, there 
was one pediatric HCT center in Vilnius performing allo- and auto-
HCT. The number of pediatric HCT beds increased from 4 in 2013 
to 6 beds in 2018 (50.0% increase). Calculated per 10 M pediatric 
population, the number of pediatric HCT beds was 73.6 in 2013 and 
119.3 in 2018 (62.1% increase due to an increase in the number of 
beds and decrease of the pediatric population). An increasing trend 
was observed in the number of allo-HCT from 9 in 2013 to 11 in 
2018 (22.2% increase). The calculated ratio of allo-HCT for 10 M 
of the pediatric population increased from 165.5 in 2013 to 218.7 in 
2018 (32.1% increase). A decrease of 37.5% was observed in auto-
HCT, from 8 in 2013 to 5 in 2018. When calculated for 10 M of the 
pediatric population, a 32.4% decrease in auto-HCT was observed 
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(from 147.1 in 2013 to 99.4 in 2018). The total number of auto-HCT 
and allo-HCT calculated per 10 M pediatric population did not change 
(312.6 in 2013 and 318.1 in 2018; 1.7% insignificant increase).
The main indication for HCT in 2013 was ALL, Hodgkin lymphoma 
(HL), and ES. In 2018, less HCT was performed in patients with 
ALL, HL, ES, and NBL, while more due to PID. No transplantations 
were performed due to CML in 2013 and 2018, while one HCT was 
performed due to SAA/BFM in 2013 and two in 2018.
In 2013, Lithuania was among the countries with a very high 
transplant rate per 10 M of the pediatric population. In addition, in 
2018 two more pediatric transplant beds were available (the highest 
number of transplant beds per 10 M of pediatric population, among 
analyzed countries). We assume that the number of pediatric beds 
and the number of transplants cover the needs. However, it should 
be noted that the Vilnius center also performs transplants for children 
from Latvia for standard indications except PID.
Poland
Polish pediatric population has not changed significantly between 
2013 and 2018 (7.005 M in 2013 and 6.874 M in 2018; -1.9%). In 
2013, there were five pediatric HCT centers (Bydgoszcz, Poznan, 
Krakow, Lublin, and Wroclaw) performing auto- and allo-HCT. 
In 2015, the center in Wroclaw moved to a new location with the 
simultaneous increase of pediatric transplant beds (five new beds). 
In 2018, a new pediatric HCT center was established in Warsaw with 
five pediatric beds. Therefore, in 2018, six pediatric HCT centers 
were active in Poland (five performing allo- and auto-HCT; one 
performing auto-HCT). The total number of pediatric transplant beds 
increased from 35 in 2013 to 45 in 2018 (28.6% increase). Calculated 
per 10 M of the pediatric population, the number of pediatric HCT 
beds increased from 50.0 in 2013 to 65.5 in 2018 (31.0% increase). 
An increasing trend was also observed in the number of allo- and 
auto-HCT. A total of 114 allo-HCT were performed in 2013, while 146 
in 2018 (28.1% increase). When calculated per 10 M of the pediatric 
population, a 30.5% increase was observed (from 162.7 allo-HCT per 
10 M of the pediatric population to 212.4 allo-HCT per 10 M pediatric 
population). In the case of auto-HCT, 34 procedures were performed 
in 2013, while 39 in 2018 (14.7% increase). When calculated for 10 M 
of the pediatric population, a 16.9% increase was observed (from 
48.5 auto-HCT per 10 M pediatric population to 56.7 auto-HCT per 
10 M pediatric population). The total number of auto- and allo-HCT 
calculated per 10 M pediatric population increased from 211.3 in 
2013 to 269.1 in 2018 (27.4% increase).
The main indication for allo-HCT was ALL and AML, while NBL 
for auto-HCT, both in 2013 and 2018. Both in 2013 and 2018, two 
transplantations due to CML were performed yearly. SAA/BMF was 
an indication for 15 allo-HCT in 2013 and 17 allo-HCT in 2018.
A significant increase in the number of pediatric transplant beds and 
the number of HCT in Poland was observed in analyzed years. Despite 
an observed increase, the number of HCT per 10 M of the pediatric 
population in both 2013 and 2018 ranks Poland in a group of countries 
with a high number of transplants (201–300 transplants per 10 M of 
the pediatric population). We expect a further increase in the number 
of transplants. Probably the number of centers, pediatric beds, and 
transplants still does not completely cover the country’s needs.
Romania
Romanian pediatric population has not changed significantly 
between 2013 and 2018 (3.786 M in 2013 to 3.681 M in 2018; -2,8%). 
Between 2013 and 2018, the number of HCT centers performing 
allo- and auto-HCT did not change as there were two centers: 
one in Bucharest (pediatric only) and one in Timisoara (joint adult-
pediatric center) performing allo- and auto-HCT. The total number 
of pediatric transplant beds increased from 9 in 2013 to 11 in 2018 
(22.2% increase). Calculated per 10 M pediatric population, the 
number of beds increased from 23.8 in 2013 to 29.9 in 2018 (25.7% 
increase). A significant increase was observed in the number of allo- 
and auto-HCT. Nine allo-HCT were performed in 2013, while 18 in 
2018 (100.0% increase). When calculated per 10 M of the pediatric 
population, a 105.7% increase was observed (from 23.8 allo-HCT per 
10 M pediatric population to 48.9 allo-HCT per 10 M of the pediatric 
population). In the case of auto-HCT, 13 procedures were performed 
in 2013, while 22 in 2018 (69.2% increase). When calculated for 10 M 
of the pediatric population, a 74.1% increase was observed (from 
34.3 auto-HCT per 10 M of the pediatric population to 59.8 auto-HCT 
per 10 M of the pediatric population). The total number of auto- and 
allo-HCT calculated per 10 M pediatric population increased from 
58.1 in 2013 to 108.7 in 2018 (87.0% increase).
In 2013, the main indication for allo-HCT was AML, while NBL and 
HL for auto-HCT. In 2018, the main indication for allo-HCT was ALL 
(a significant increase from 2 to 6 procedures) and AML, while NBL 
and HL for auto-HCT (a significant increase from 5 to 12 procedures 
for NBL and increase from 5 to 10 procedures for HL). One allo-HCT 
was performed due to CML in 2013, while none in 2018. SAA/BMF 
was an indication for two allo-HCT in 2013 and four allo-HCT in 2018.
A significant increase in the number of beds and number of HCT 
has been observed in analyzed years. Despite an observed increase, 
the number of transplants per 10 M of the pediatric population in 
both 2013 and 2018 shifted Romania from the group of countries 
with a low number of transplants (1–100 transplants per 10 M of the 
pediatric population) to a moderate number of transplants (101–200 
transplantations per 10 M pediatric population). Our data suggest 
that the number of pediatric beds and the number of transplants do 
not cover country needs, and we expect a significant increase in the 
number in allo- and auto-HCT.
Slovakia
The Slovakian pediatric population has not changed significantly 
between 2013 and 2018 (1.075 M in 2013 to 1.062 M in 2018; 
−1.2%). Between 2013 and 2018, there was one pediatric HCT 
center performing both auto- and allo-HCT, located in Bratislava. The 
total number of pediatric transplant beds did not change in analyzed 
years, as there were six pediatric HCT beds. Calculated per 10 M 
of the pediatric population, the number of beds also did not change 
(55.8 in 2013 and 56.5 in 2018; 1.2% decrease due to pediatric 
population decrease). A significant increase was observed in the 
number of allo- and auto-HCT. Twelve allo-HCT were performed in 
2013, while 14 in 2018 (16.7% increase). When calculated per 10 M 
of the pediatric population, an 18.0% increase was observed (from 
111.6 allo-HCT per 10 M of the pediatric population to 131.7 allo-
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HCT per 10 M of the pediatric population). In the case of auto-HCT, 
5 procedures were performed in 2013, while 11 in 2018 (120.0% 
increase). When calculated for 10 M of the pediatric population, 
a 122.6% increase was observed (from 46.5 auto-HCT per 10 M of 
the pediatric population to 103.5 auto-HCT per 10 M of the pediatric 
population). The total number of auto- and allo-HCT calculated per 
10 M pediatric population increased from 158.1 in 2013 to 235.2 in 
2018 (48.8% increase).
In 2013, the main indication for allo-HCT was ALL, AML, and PID, 
while NBL for auto-HCT. In 2018, the main indication for allo-HCT 
was ALL, AML, and MDS, while NBL for auto-HCT (a significant 
increase from 3 to 8 procedures). One allo-HCT was performed due 
to SAA/BMF in 2013 and 2018 while none due to CML.
No changes were observed in the number of pediatric HCT beds. 
Despite an observed increase in the number of transplants per 10 M 
of the pediatric population in both 2013 and 2018 shifted Slovakia 
from the group of countries with a moderate number of transplants 
(101–200 transplantations per 10 M of the pediatric population) to 
a high number of transplants (201–300 transplants per 10 M of the 
pediatric population). We expect a further increase in the number 
of transplants. Probably the number of centers, pediatric beds, and 
transplants does not cover the country’s needs.
Slovenia
Slovenian pediatric population has not changed significantly between 
2013 and 2018 (0.356 M and 0.366 M respectively; 3.0% insignificant 
increase). There is one joint adult-pediatric center performing allo- 
and auto-HCT in children (Ljubljana). The total number of pediatric 
HCT beds did not change (two beds). When calculated per 10 M 
pediatric population, it was 56.2 in 2013 and 54.6 in 2018 (2.9 
insignificant decrease due to population increase). A decrease of 
37.5% for allo-HCT was observed between 2013 (8 procedures) 
and 2018 (5 procedures). When calculated per 10 M of the pediatric 
population, it was 39.3% decrease (from 224.7 allo-HCT per 10 M 
pediatric population to 136.4 allo-HCT per 10 M pediatric population). 
In the case of auto-HCT, a significant (150.0%) increase was 
observed (from 2 procedures in 2013 to 5 procedures in 2018). When 
calculated per 10 M of the pediatric population, a 142.8% increase 
was observed (from 56.2 auto-HCT per 10 M pediatric population 
to 136.4 auto-HCT per 10 M pediatric population). The total number 
of auto- and allo-HCT calculated per 10 M pediatric population 
insignificantly decreased from 280.9 in 2013 to 272.8 in 2018 (2.9%).
In 2013, the main indication for allo-HCT was ALL, AML, and SAA/
BMF (two procedures each), and one transplantation was performed 
for PID and metabolic disorder, respectively. In the case of auto-HCT, 
one procedure was performed due to NBL and one due to ES. In 
2018, four transplantations were performed due to ALL and one due 
to PID, while four auto-HCT due to NBL and three auto-HCT (not 
shown in the table as another indication) due to other solid tumors. 
No procedures due to CML were performed in 2013 and 2018. In 
2018, there were no transplantations in SAA/BMF patients.
The number of pediatric transplant beds and the number of 
transplantations in Slovenia did not change. The number of 
transplants per 10 M pediatric population in both 2013 and 2018 ranks 
Slovenia in a group of countries with a high number of transplants 
(201–300 transplants per 10 M of the pediatric population), taking 
into consideration a small pediatric population, we think that one 
center, the number of pediatric beds and the number of transplants 
cover the country needs at present time. However, due to the global 
upward trend in transplant activity, the number of transplant beds 
may need to be increased in the near future.
Ukraine
Ukrainian pediatric population insignificantly decreased from 
7.990 M in 2013 to 7.609 M in 2018 (4.8% decrease). According to 
the obtained data, a complete analysis was not possible. Between 
2013 and 2018, the number of HCT centers performing allo- and 
auto-HCT did not change – there were three centers in Kyiv: only 
one pediatric and two joint adult-pediatric centers performing allo- 
and auto-HCT. Allo-HCT from unrelated donors is not performed 
in Ukraine and patients are transplanted in foreign countries 
(Belorussia, Italy, Israel, Poland, and Turkey). The total number of 
pediatric transplant beds increased from 9 in 2013 to 11 in 2018 
(22.2% increase). Calculated per 10 M of the pediatric population, 
the number of pediatric HCT beds increased from 11.3 in 2013 
to 14.4 in 2018 (28.3% increase). A decrease of 19.0% for allo-
HCT was observed between 2013 (21 procedures) and 2018 (17 
procedures). When calculated per 10 M of the pediatric population, 
it was a 15.0% decrease (from 26.3 allo-HCT per 10 M pediatric 
population to 22.3 allo-HCT per 10 M pediatric population). In 
the case of auto-HCT, a 10.3% increase was observed (from 39 
procedures in 2013 to 43 procedures in 2018). When calculated per 
10 M of the pediatric population, a 15.8% increase was observed 
(from 48.8 auto-HCT per 10 M of the pediatric population to 56.5 
auto-HCT per 10 M of the pediatric population). The total number 
of auto-HCT and allo-HCT calculated per 10 M pediatric population 
increased from 75.1 in 2013 to 78.9 in 2018 (5.0%), but it was 
connected with a 4.8% pediatric population decrease. It ranking 
Ukraine to countries with a low number of transplantations (1–
100 HCT per 10 M of the pediatric population).
In 2018, the rate of auto-HCT per 10 M of pediatric population (56.5) 
was close to respective rates in Croatia (69.8), Hungary (70.0), 
Romania (59.8), and Poland (56.7) and significantly lower than in 
Czech Republic (184.7), Slovenia (136.4), and Slovakia (103.5). 
In the case of allo-HCT in 2018, the rate per 10 M of the pediatric 
population was very significantly lower (22.3) than in other countries 
(Romania -48.9; Lithuania -218.7) confirming deficiency in the allo-
HCT setting. It was also seen in the migration of Ukrainian patients to 
other countries for allo-HCT from unrelated donors.
Summary
Over the past 5 years, the total number of pediatric transplant centers 
increased by one (in Poland) in nine studied countries (Czech 
Republic, Croatia, Hungary, Lithuania, Poland, Romania, Slovakia, 
Slovenia, and Ukraine). During this period, the number of beds 
increased from 96 to 112 (16.7%): Lithuania (50% increase, 2 beds), 
Poland (28.6% increase, 10 beds), Romania (22.2% increase, 2 
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beds), and Ukraine (22.2% increase, 2 beds). Calculated per 10 M 
of the pediatric population, an increase in allo-HCT was observed 
from 95.1 to 119.7 (25.9% increase), highest in Croatia (+338.7%), 
Romania (+105.7%), Lithuania (+32.1%), and Poland (+30.5%). 
Calculated per 10 M of pediatric population, a significantly lower 
increase in the number of auto-HCT was observed in analyzed 
countries: from 64.8 to 72.7 (12.2% increase), highest in Slovenia 
(142.8% increase), Slovakia (122.5% increase), Romania (74.1% 
increase), Poland (16.9% increase), Ukraine (15.8% increase), and 
Croatia (9.7% increase). Analyzing the total of auto- and allo-HCTs, 
an increase of 20.3% was observed (from 159.9 in 2013 to 192.4 
per 10 M of the pediatric population in 2018). The largest increase 
was observed in Croatia (+133.1%), Romania (+87.0%), Slovakia 
(+48.8%), and Poland (+27.4%), followed by Czech Republic (+9.4%) 
and Ukraine (+5.0%). A decrease was observed in Hungary (-19.1%), 
and no change in Lithuania and Slovenia (Fig. 2).
Discussion
This is the first report that demonstrates the development of HCT 
activity in Central-East European countries in the pediatric population 
in two-time points (2013 and 2018). The EBMT activity surveys 
conducted since 1990 indicate a steady increase in the number of 
HCT, which exceeded 47,000 transplantations per year in 2018 [3, 8]. 
This expansion is much more pronounced in allo-HCT (7.1% in 
2018 when compared to 2017) setting than in the auto-HCT setting 
(2.4% in 2018 when compared to 2017), especially in the pediatric 
population (9.4% allo-HCT vs. 3.0% auto-HCT) [3]. When compared 
to 2003 and 2013 activity reports, our analysis shows a significant 
increase in transplant activity in the pediatric population in Central-
East European countries in 2018, especially in the allo-HCT setting 
[2, 3, 7].
Compared to 2013, we observed an increase in the number of 
transplants due to ALL, MDS, HL, and SAA/BFM in 2018, which was 
also observed in other countries in respective indications [2, 3]. The 
number of transplants due to NBL also increased, while metabolic 
diseases were at the same level. However, a significant decrease in 
the number of pediatric transplants was observed due to non-HL when 
compared to data from the 2013 and 2018 annual activity surveys 
in the general population [2], probably due to the development of 
the targeted therapy. The introduction of tyrosine kinase inhibitors 
has marked a revolutionary step in CML patients resulting in the low 
number of transplants when compared with previous activity reports 
[2, 3, 9].
Our analysis suggests that in the Czech Republic, Hungary, Lithuania, 
and Slovenia the infrastructure and the number of HCT cover the 
needs. In other countries, especially in Romania and Ukraine, the 
number of HCT per 10 M of the pediatric population is lower and 
there is a real need for the increase.
In the last EBMT activity survey report [3], the most impressive growth 
was observed in hematopoietic cellular therapies, especially in the 
use of CAR-T. Probably in the future, the new cellular therapies will 
cause a further increase for pediatric transplant beds and aggravate 
their shortage in countries with the lowest rates.
Fig. 2. The total number of auto-HCT and allo-HCT per 10M pediatric population in reported  countries in 2013 and 2018
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Conclusions
We have shown, over the years 2013 and 2018, in some countries 
of Central-Eastern Europe that there was a significant increase 
in transplant activity, especially in those with the lower rates. This 
increase is associated with an increase of transplant activity in 
centers already existing in 2013, especially in the allo-HCT setting. 
The rise of activity was significantly less influenced by the creation 
of new transplant centers or the increase in the number of pediatric 
transplant beds. Our analysis indicates that in Czech Republic, 
Hungary, Lithuania, and Slovenia the infrastructure and the number 
of HCT cover the needs, whereas in other countries, especially in 
Romania and Ukraine, the number of HCT and infrastructure are in 
a real need for the increase.
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